Sabra Health Care REIT Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sabra Health Care REIT (SBRA).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

3S.Buy

4Buy

8Hold

Consensus RatingNeutral# Analysts15Avg. Consensus PT$21Upside to Avg. PT+5.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	Wells Fargo	James Feldman	PT Cut	Overweight	$23→$21
Oct 13, 2026	UBS	Michael Goldsmith	PT Cut	Neutral	$21→$20
Oct 13, 2026	Barclays	Richard Hightower	PT Cut	Equal-Weight	$23→$21
Aug 31, 2026	Barclays	Richard Hightower	PT Raise	Equal-Weight	$21→$23
Aug 31, 2026	Baird	Vikram Malhotra	PT Raise	Neutral	$20→$21
Aug 6, 2026	Raymond James	David Rodgers	Upgrade	Underperform→Market Perform	—
Jul 22, 2026	Baird	Wesley Golladay	PT Raise	Neutral	$22→$23
Jul 22, 2026	Truist Securities	Michael Lewis	PT Raise	Buy	$22→$24
Jul 22, 2026	Citizens	Aaron Hecht	PT Raise	Market Outperform	$23→$25
Jul 8, 2026	UBS	Michael Goldsmith	PT Cut	Neutral	$22→$21
Jul 8, 2026	Truist Securities	Michael Lewis	Upgrade	Hold→Buy	$22
Jul 7, 2026	Barclays	Richard Hightower	Initiate	Equal-Weight	$21
Jun 23, 2026	Citigroup	Nick Joseph	Downgrade	Buy→Neutral	$24→$19
Jun 18, 2026	Scotiabank	Nicholas Yulico	PT Cut	Sector Perform	$22→$19
Jun 17, 2026	Raymond James	David Rodgers	Reinstates	Market Perform→Underperform	—
Jun 1, 2026	Wells Fargo	John Kilichowski	PT Raise	Overweight	$22→$23
May 21, 2026	Scotiabank	Nicholas Yulico	PT Raise	Sector Perform	$21→$22
May 13, 2026	UBS	Michael Goldsmith	PT Raise	Neutral	$21→$22
May 11, 2026	Cantor Fitzgerald	Richard Anderson	PT Raise	Neutral	$21→$22
Mar 26, 2026	Wells Fargo	John Kilichowski	PT Raise	Overweight	$21→$22

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Sabra Health Care REIT, Lowers Price Target to $21

Wells Fargo analyst James Feldman maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Overweight and lowers the price target from $23 to $21.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on Sabra Health Care REIT, Lowers Price Target to $20

UBS analyst Michael Goldsmith maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and lowers the price target from $21 to $20.

Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Lowers Price Target to $21

Barclays analyst Richard Hightower maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Equal-Weight and lowers the price target from $23 to $21.

Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Raises Price Target to $23

Barclays analyst Richard Hightower maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Equal-Weight and raises the price target from $21 to $23.

Benzinga Newsdesk

PRO
Baird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $21

Baird analyst Vikram Malhotra maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and raises the price target from $20 to $21.

Benzinga Newsdesk

This Danaos Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Wall Street analysts change outlook on top names. See all rating changes, upgrades, downgrades and initiations at Benzinga's analyst ratings page.

Avi Kapoor

Sabra Health Care REIT Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Sabra Health Care REIT Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Sabra Health Care REIT, Lowers Price Target to $21

PRO
UBS Maintains Neutral on Sabra Health Care REIT, Lowers Price Target to $20

PRO
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Lowers Price Target to $21

PRO
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Raises Price Target to $23

PRO
Baird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $21

This Danaos Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

People Also Watch

People Also Watch

Sabra Health Care REIT Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Sabra Health Care REIT Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWells Fargo Maintains Overweight on Sabra Health Care REIT, Lowers Price Target to $21

PROUBS Maintains Neutral on Sabra Health Care REIT, Lowers Price Target to $20

PROBarclays Maintains Equal-Weight on Sabra Health Care REIT, Lowers Price Target to $21

PROBarclays Maintains Equal-Weight on Sabra Health Care REIT, Raises Price Target to $23

PROBaird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $21

This Danaos Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

People Also Watch

People Also Watch

PRO
Wells Fargo Maintains Overweight on Sabra Health Care REIT, Lowers Price Target to $21

PRO
UBS Maintains Neutral on Sabra Health Care REIT, Lowers Price Target to $20

PRO
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Lowers Price Target to $21

PRO
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Raises Price Target to $23

PRO
Baird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $21